Axovia Therapeutics Presents New Preclinical Data for AXV-101 for the Treatment of Blindness Associated with BBS Mutations at ASGCT - Axovia Therapeutics London, UK – May 13, 2025 – Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced the presentation of new preclinical...

When the work of centre members has an impact on people. News from Dr Victor Hernandez and Axovia Therapeutics. #gentherapy #cengem

axoviatherapeutics.com/axovia-thera...